News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Chiron Corporation (CHIR) Licenses Technology From Infectio Diagnostic Inc. For Bacterial Detection System For Platelets

10/19/2005 5:09:35 PM

EMERYVILLE, Calif. and QUEBEC, Jan. 5 /PRNewswire-FirstCall/ -- Chiron Corporation and Infectio Diagnostic Inc. (IDI) today announced that Chiron has licensed IDI's proprietary nucleic acid-based technology for the rapid detection of bacterial contamination in platelets and blood products. Under the terms of the agreement, Chiron will obtain a license to all current and future products for the detection of bacteria in platelets and blood for transfusion based upon the technology. In addition, IDI will transfer the technology including R&D and manufacturing to Chiron over the next two years. Financial terms of the agreement were not disclosed.

"The acquisition of this technology represent a significant step in expanding Chiron's commitment to blood safety," said Jack Goldstein, president, Chiron Blood Testing. "Rapid detection of bacteria in platelets is critical given the five-day shelf life of platelet concentrates. Bacterial contamination is the leading cause of transfusion-related illness, and successful development of a nucleic acid-based system that has the ability for same-day results, will provide the blood industry with an important tool in protecting patient health worldwide."

"IDI is very proud that Chiron chose our proprietary technology for screening bacteria in platelets," said Jean-Pierre Gayral, president, IDI. "We are confident in Chiron's ability to commercialize a very powerful same-day test for this critical blood safety concern. For IDI, 2003 has been an outstanding year with the commercialization of our first two products and the completion of this agreement with Chiron."

IDI's proprietary nucleic acid technology for universal detection of microorganisms is used to directly detect the DNA of bacterial species known to contaminate platelets. The technology is currently in development.

About Bacterial Contamination

Bacterial contamination of platelets is the number one cause of morbidity and mortality from a transfusion-transmitted infection. It is estimated that as many as one in 4,000 transfusions lead to a severe septic reaction and as many as one in 17,000 transfusions can lead to death due to bacterial contamination. Platelets, which are used to treat patients with serious illnesses such as cancer and leukemia, are the blood component most vulnerable to bacterial contamination since they must be stored at room temperature to retain their blood clotting functions. The risk of receiving a bacteria contaminated platelet may be 50- to 250- fold higher than the combined risk of transfusion-related infections associated with HIV and hepatitis B and C. As a result, the American Association of Blood Banks has implemented a new standard requiring bacterial quality control testing of platelets starting in March 2004.

About Chiron Blood Testing

Chiron Blood Testing is dedicated to preventing the spread of infectious diseases through the development of novel blood-screening tools that protect the world's blood supply. Chiron's Procleix(R) assays and systems, developed in collaboration with Gen-Probe Incorporated, utilize state-of-the-art nucleic acid testing (NAT) technology to detect RNA and DNA in donated blood, plasma, organs and tissue during the very early stages of infection, when infectious agents are present but cannot be detected by immunodiagnostic screening technologies. Through its joint business with Ortho-Clinical Diagnostics, Chiron also develops and markets a line of immunoassay screening, diagnostic, and supplemental hepatitis and retrovirus tests. For more information about Chiron Blood Testing visit,

About Infectio Diagnostic Inc.

Infectio Diagnostic Inc. (IDI) is a privately held Canadian company. The company is specialized in the development of nucleic acid-based tests for the rapid detection of bacterial, fungal and parasite human infections as well as for the detection of antibiotic resistance. The IDI product line is expected to provide a complete diagnostic result within one hour rather than the usual two to three days required by current methods. IDI has launched its first two products in North America in 2003: IDI Strep B(TM) and IDI MRSA(TM). Both are based on IDI's proprietary technologies. IDI pursues product development through its own internal diagnostic products and strategic alliances with companies such as Chiron Corporation. For more information visit:

This news release contains forward-looking statements, including statements regarding sales growth, product development initiatives, new product marketing, acquisitions and in- and out-licensing activities that involve risks and uncertainties and are subject to change. A full discussion of the Chiron's operations and financial condition, including factors that may affect its business and future prospects, is contained in documents the company has filed with the SEC, including the form 10-K for the year ended December 31, 2002 and the form 10-Q for the quarter ended September 30, 2003, and will be contained in all subsequent periodic filings made with the SEC. These documents identify important factors that could cause the company's actual performance to differ from current expectations, including the outcome of clinical trials, regulatory review and approvals, manufacturing capabilities, intellectual property protections and defenses, stock-price and interest-rate volatility, and marketing effectiveness. In particular, there can be no assurance that Chiron will increase sales of existing products, successfully develop and receive approval to market new products, or achieve market acceptance for such new products. There can be no assurance that Chiron's out-licensing activity will generate significant revenue, nor that its in-licensing activities will fully protect it from claims of infringement by third parties. In addition, the company may engage in business opportunities, the successful completion of which is subject to certain risks, including shareholder and regulatory approvals and the integration of operations.

Consistent with SEC Regulation FD, we do not undertake an obligation to update the forward-looking information we are giving today.

Note: Procleix is a trademark of Chiron Corporation. IDI Strep B and IDI MRSA are trademarks of Infectio Diagnostic Inc.

Chiron Corporation

CONTACT: Chiron Corporate Communications & Investor Relations, Media,+1-510-923-6500, or Investors, +1-510-923-2300, or Jean-Pierre Gayral,President of Infectio Diagnostic Inc, +1-418-681-4343

Read at

comments powered by Disqus